SEC Comment Letter for Zentalis Pharmaceuticals, Inc. (ZNTL) (CIK 0001725160) (ZNTL) — Jun 29, 2022
Zentalis Pharmaceuticals, Inc. (ZNTL) (CIK 0001725160)
Date: June 29, 2022 · CIK: 0001725160 · Accession: 0000000000-22-006963
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-39263
Letter
United States securities and exchange commission logo June 29, 2022 Melissa Epperly Chief Financial Officer Zentalis Pharmaceuticals, Inc. 1359 Broadway Suite 1710 New York, New York 10018 Re:Zentalis Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed February 24, 2022 File No. 001-39263 Dear Ms. Epperly: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
June 29, 2022
Melissa Epperly
Chief Financial Officer
Zentalis Pharmaceuticals, Inc.
1359 Broadway
Suite 1710
New York, New York 10018
Re:Zentalis Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2021
Filed February 24, 2022
File No. 001-39263
Dear Ms. Epperly:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences